Psychedelic Pharmacology And Neuroscience

PSYCHEDELIC PHARMACOLOGY AND NEUROSCIENCE

We provide a space for reflection in which future prospects for research in neuroscience and psychedelic pharmacology are explored. This allows participants to gain a comprehensive understanding of how these emerging areas are revolutionizing our understanding of the human mind and opening new avenues for therapy and mental wellness. We emphasize the importance of understanding the interaction between psychedelic substances and the human brain from neuroscientific and pharmacological perspectives, thus enriching the exploration of these substances from a scientific and clinical approach.

This module will provide participants with an understanding and information on the pharmacology of psychedelic substances, allowing them to explore their therapeutic potential and their impact on the brain and mind. As well as the interactions between psychedelic substances and the human brain from a neuroscientific perspective.

The therapeutic applicability of psychedelic substances will also be explored in depth, with a focus on how the underlying pharmacology may be linked to therapeutic outcomes in conditions such as depression and anxiety. The neurobiological basis and pharmacological mechanisms underlying the psychedelic effects of substances such as LSD, psilocybin and MDMA will be explored. Participants will discover how these substances interact with brain receptors and how those interactions translate into unique psychedelic experiences.

PROGRAM

By participating in this module, students will have access to a better understanding of these topics:

FACILITATORS

Jose Carlos Bouso

Jos茅 Carlos Bouso is a Clinical Psychologist and PhD in Pharmacology. He developed his scientific activity at the Universidad Aut贸noma de Madrid, at the Instituto de Investigaci贸n Biom茅dica IIB-Sant Pau in Barcelona and at the Instituto Hospital del Mar de Investigaciones M茅dicas de Barcelona (IMIM). During this time, he developed studies on the therapeutic effects of MDMA (“ecstacy”) and psychopharmacological studies on the acute and long-term neuropsychiatric effects of many substances, both synthetic and plant-derived. As Scientific Director of ICEERS, Jos茅 Carlos coordinates studies on the potential benefits of psychoactive plants, mainly cannabis, ayahuasca and ibogaine, with the aim of improving public health. He is co-author of numerous scientific articles and several book chapters. He is also a member of the MARC (Medical Anthropology Research Center) at the Universitat Rovira i Virgili in Tarragona, visiting professor in the mental health program at the Faculty of Medicine of the University of S茫o Paulo in Riber茫o Preto, Brazil, and vice-president of the Society of Clinical Endocannabinology (SEC).

Oscar Soto

脫scar Soto Angona is a psychiatrist, researcher and therapist. Graduated in Medicine from the University of Valladolid, he specialized in Psychiatry at the Vall d’Hebron University Hospital, where he has also developed research and clinical activity in the Resistant Depression Program. Doctoral candidate at the Universitat Aut贸noma de Barcelona, his interest is focused on the phenomenology of altered states of consciousness induced by psychedelics, and their therapeutic utility. He has been or is a sub-investigator or therapist in several clinical trials with psychedelics, including esketamine, psilocybin, MDMA, and 5MeoDMT. He is president and founder of the Spanish Society of Psychedelic Medicine.